Bentasil

Quick links to important sections

Bentasil

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bentasil

Quick Facts: Bentasil

Property Description
Active ingredients Anethole, Cineole (Eucalyptol), Menthol
Form Oil-based preparation (e.g., nasal drops, solution)
Pharmacological class Local Analgesic, Decongestant, Antiseptic Agent
Common use Symptomatic relief of upper respiratory discomfort and congestion
Origin Natural origin (Phytoderivative)

What is Bentasil and its Pharmacological Classification?

Bentasil is defined as a fixed-dose combination product containing a synergistic blend of volatile aromatic compounds, which is broadly classified as a local agent. It belongs to the high-level class of medicines recognized for their combined decongestant, antiseptic, and local analgesic properties for the upper respiratory tract. This substance is a phytoderivative, meaning its active components are sourced from natural origin, specifically belonging to the Terpenes and Terpenoids structural classes.

Active Composition and Drug Form (Anethole, Cineole, Menthol)

Bentasil's identity is fundamentally defined by its three active ingredients: Anethole (an aromatic ether), Cineole (formally known as 1,8-Cineole), and Menthol (the L-Menthol stereoisomer). Cineole is an essential oil component commonly referred to as Eucalyptol. This multicomponent blend is typically formulated as an oil-based preparation, delivered for local use as nasal drops or a topical solution. Menthol acts on specific sensory receptors, a mechanism that provides the characteristic cooling sensation.

The General Purpose of Bentasil

The primary general purpose of Bentasil is to provide symptomatic relief for discomfort and congestion experienced in the upper respiratory tract, such as during periods of common cold or seasonal irritation. This benefit stems from the drug's purely localized physiological effects, avoiding systemic action. The unique oil-based vehicle ensures a controlled, sustained local presence of the aromatic components on the mucous membranes. By utilizing these established mechanisms, the medicine serves to soothe irritated tissues and promote the sensory perception of cleared airways.

What side effects are possible with Bentasil?

Possible side effects and safety information

The officially documented safety profile of Bentasil, derived from regulatory data concerning its volatile aromatic components (Anethole, Cineole, Menthol), is primarily classified under Skin and Subcutaneous Tissue Disorders and Immune System Disorders.

Official Adverse Reactions and Classifications

Adverse reactions associated with Bentasil are often related to its localized effects. These include common, expected local effects like a stinging or burning sensation and localized skin irritation or redness at the site of application. Regulatory documents often classify the frequency of these reactions as Not Known, although the sensations are noted to be generally mild and may lessen over time.

Classification Tier Specific Reaction Examples
Serious Adverse Reactions Signs of severe hypersensitivity reactions, including difficult breathing (dyspnea), hives (urticaria), or swelling of the face, lips, tongue, or throat.
Local Expected Reactions Local skin irritation, redness, and a temporary burning sensation at the application site.

Regulatory Safety Considerations

The safety profile includes constraints related to special populations and product use. Regulatory guidance advises against use in certain pediatric populations, such as children below a specific age, due to known safety risks associated with volatile essential oils. Additionally, the label advises individuals with a known allergy to any component to avoid the product.

Safety limitations also stipulate that use should be discontinued if the initial symptoms fail to improve after a set period, or if local effects worsen to include blistering or severe pain. Flammability warnings are also included in the product's official safety information due to the volatile and oil-based nature of the formulation.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Regulatory documentation emphasizes that immediate medical attention must be sought for any suspected overdose of Bentasil due to the potential for severe systemic toxicity from its active volatile oil components. Contacting emergency services or a Poison Control Center is mandatory, as documented serious outcomes can develop rapidly.

Overdose manifestations, as officially documented, primarily affect the Central Nervous System (CNS) and the respiratory system. Documented CNS effects may include somnolence, ataxia, and disorientation, which can progress to stupor or loss of consciousness. Severe neurological events such as seizures and convulsions are also cited outcomes. Respiratory risks include shallow breathing and respiratory depression.

Management procedures described in official sources focus on symptomatic and supportive treatment, as no specific antidote is known. Hospital monitoring and observation are required to manage potential complications. A critical regulatory note highlights that children are highly vulnerable to these toxic effects, with convulsions being a common and serious consequence even after small accidental ingestions.

Therapeutic Uses of Bentasil

What Bentasil Treats: Main Uses and Benefits

Bentasil is applied across domains where additional symptomatic support is needed, primarily for temporary relief during acute or episodic changes associated with the common cold. The therapeutic use of such products addresses the temporary management of symptoms related to upper respiratory tract irritation.

This medication is generally used to help manage minor throat discomfort and irritation, a frequent and irritating cough, and supportive relief for nasal congestion. The primary purpose is addressing symptoms related to physical discomfort in the throat.

“The supportive relief provided may contribute to improved comfort during periods of heightened symptoms.”

Clinical Context for Use The medicine is relevant in clinical settings that involve acute or unstable symptom patterns, such as the sudden onset of a cold. Applied during phases when symptoms become more noticeable, it provides supportive relief that helps improve day-to-day comfort and helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. Health Canada Guidance Document on Drug Facts

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Status

Official regulatory documentation defines eligibility for Bentasil (a combination of Menthol, Cineole, and Anethole) by establishing specific exclusions based on age, physiological state, and pre-existing conditions.

Classification Population or Condition
Absolute Contraindicated Infants and children under 2 years of age
Absolute Contraindicated Patients with known hypersensitivity to the active substances or excipients
Absolute Contraindicated Individuals with a history of bronchial asthma or epilepsy
Not Recommended Women who are pregnant or breastfeeding

Age-Related Rules

The most stringent regulatory restriction is the Contraindication for children under two years old, enforced due to the risk of laryngeal and bronchial spasm (reflex apnoea) associated with volatile oils. Use in children aged 2 to 12 years is typically restricted to lower labeled concentrations and must be carried out under adult supervision. Adults and adolescents (usually 12 years and older) are generally permitted to use the medicine, provided no other contraindications are present.

Physiological and Comorbidity Restrictions

Official labeling mandates that the medicine must not be used by patients with a pre-existing unstable condition, such as a history of bronchial asthma or epileptic seizures. Use is formally listed as Not Recommended during pregnancy and lactation due to the lack of sufficient human safety data to definitively establish safety for these populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory labeling for Bentasil, a local-acting oil-based preparation, documents no specific systemic drug–drug interactions with other medicinal products.

This absence of documented interactions in authoritative government sources is structurally consistent with the medicine's route of administration. Because Bentasil is applied locally to the upper respiratory tract, the active components—Anethole, Cineole, and Menthol—exhibit negligible systemic exposure.

This negligible systemic availability means the drug does not interfere with the major systemic pharmacokinetic processes (such as drug metabolism via CYP450 enzymes) or drug transport mechanisms responsible for the clearance of co-administered systemic medicines.

Interaction Status by Regulatory Classification

The product's official interaction profile is defined by the following statuses as determined by regulatory agencies:

  • Contraindicated Combinations: None are formally listed. The regulatory documents do not prohibit co-administration with any specific systemic medicine due to an interaction risk.
  • Exposure Modification: No substances are documented to either increase or decrease the systemic exposure ( AUC or C max) of Bentasil or co-administered drugs.
  • Timing Constraints: There are no mandatory dose separation or administration timing requirements specified in the official labeling for Bentasil and other products.

This profile confirms that no specific restrictions, prohibitions, or population-dependent interaction cautions are documented in the product’s governmental prescribing information.

Mechanism of Action

Bentasil, which corresponds to the compound belumosudil mesilate, functions as a selective inhibitor of the rho-associated, coiled-coil containing protein kinases (ROCKs). Its primary biological target is the ROCK2 isoform, exhibiting a substantially greater affinity for ROCK2 over ROCK1.

At the intracellular level, this inhibition blocks the ROCK-mediated phosphorylation of downstream substrates. This action interrupts various molecular pathways involved in cellular signaling, notably those governing cytoskeletal dynamics and gene expression in immune cells. One downstream cascade involves the down-regulation of phosphorylation of transcription factors, specifically STAT3 and STAT5.

This modulation of transcription factor activity leads to a shift in the balance of T-lymphocyte subsets, influencing the relative abundance of T helper 17 (Th17) cells versus regulatory T (Treg) cells. The system-level physiological consequence is an immunomodulatory effect and the attenuation of pro-fibrotic signaling pathways within affected tissues.

Dosage and Administration Information

The administration of Bentasil follows a standardized protocol, structuring its use as a local, intermittent intervention.

Administration Principles

The medicine is designated for oral administration as a lozenge, which provides a local effect on the oromucosal surfaces. The procedural requirement is to slowly dissolve one lozenge in the mouth rather than swallowing the unit whole.

Dosing Regimen and Frequency

The standard dose is fixed at one lozenge, which contains 5 mg of Menthol as the active component. The dose may be repeated every 2 hours as needed. This usage pattern defines the total intake ceiling, as it is recommended to not exceed the recommended dosage based on this frequency.

Usage Context and Population Rules

The medicine is used for providing temporary relief on an as-needed basis, reinforcing its role as a short-term, symptom-driven intervention rather than a long-term therapeutic course.

Bentasil is appropriate for adults and children 5 years and over. Administration to children younger than five years old requires prior medical consultation. These parameters define the protocol for how the medicine is administered.

Recent Clinical Evidence

Bentasil: Recent Clinical Evidence

The lozenge formulation known as Bentasil is an over-the-counter (OTC) product whose primary active ingredients include menthol, and in some varieties, eucalyptus oil. As an OTC product, evidence for its use is primarily focused on the established effects of these compounds for the temporary relief of common symptoms.

Evidence for Menthol and Eucalyptus Oil

Menthol is classified as an oral anesthetic and cough suppressant. It is studied for its temporary, localized effect on throat and mouth irritation. Research indicates that when used in lozenges, menthol may offer a cooling sensation and could help in providing a temporary, palliative reduction in the perception of sore throat discomfort.

Eucalyptus oil, an additional ingredient in certain varieties, has been investigated for its potential role in cough management. A systematic review and meta-analysis of randomized controlled trials (RCTs) involving eucalyptus products for cough found that participants reported an improvement or resolution of overall cough symptoms compared to a placebo. The evidence, however, also noted that the efficacy observed was minimal and of uncertain clinical importance, suggesting that further high-quality studies are needed to confirm the findings definitively. Eucalyptus products in these studies were generally reported to be safe for use in cough related to respiratory illnesses, with mild-to-moderate gastrointestinal symptoms sometimes reported as common adverse events.

Limitations of Evidence

It is important to understand that these products are intended for the temporary relief of minor symptoms related to a cold or cold-like illness. Clinical evidence for these active ingredients supports their role in symptom palliation, rather than addressing the underlying cause of the condition. Patients should monitor symptoms, and if they persist, worsen, or are accompanied by fever or rash, consulting a healthcare professional is recommended.

Key Studies & References

  1. Label: BENTASIL SUGAR FREE EUCALYPTUS SOFT TEXTURE - menthol eucalyptus lozenge (DailyMed/FDA)

Frequently Asked Questions (FAQ)

Common questions about Bentasil (FAQ)

Q: What is the main difference between Bentasil and other similar medicines?

A: Bentasil is officially defined by its unique combination of active ingredients: Anethole, Cineole (Eucalyptol), and Menthol. These components are categorized in regulatory documents as local agents that provide decongestant, antiseptic, and local analgesic properties. This specific composition and intended localized action may differ from that of other respiratory products.

Q: Is Bentasil considered a long-term treatment?

A: No. According to official regulatory documents, Bentasil is designated as an intervention intended for short-term, symptom-driven relief. The usage instructions state that if symptoms fail to improve after a defined period, the use of the product should be discontinued, which is consistent with its role as a temporary measure.

Q: Can Bentasil affect your sleep?

A: Official documentation for the active ingredients does not commonly include insomnia or general changes to sleep patterns as side effects when Bentasil is used as directed. However, some central nervous system effects, such as drowsiness, have been noted in regulatory literature as potential symptoms associated with accidental overdose of the active component Menthol.

Q: Is it normal to feel a bit dizzy after taking Bentasil?

A: Dizziness is not included among the commonly reported side effects in the official safety profile for the product's localized use. While safety literature notes dizziness as a potential symptom associated with accidental overdose of Menthol, it is not a documented common reaction at the labeled dosage.

Q: How is Bentasil usually supplied (e.g., tablet, capsule, liquid)?

A: Bentasil is generally supplied as an oil-based preparation. Depending on the specific product variant approved in your region, this may include forms intended for local use, such as a lozenge designed to dissolve slowly in the mouth or a solution like nasal drops.

Q: Can Bentasil be taken with food, or does it need to be taken on an empty stomach?

A: Official administration instructions for Bentasil lozenges focus on the method of use—slowly dissolving the unit in the mouth for localized effect. Regulatory labeling does not specify any mandatory timing requirements regarding its relation to meals, such as needing to be taken on an empty stomach or with food.

Q: Are there any common over-the-counter supplements that should be avoided with Bentasil?

A: The official labeling documents no specific systemic drug-drug interactions due to Bentasil's negligible systemic exposure. Regulatory sources do not list specific over-the-counter supplements, including vitamins or herbal products, that are formally contraindicated due to interaction risks.

Q: Can I take Bentasil if I have liver problems?

A: Official documentation does not list pre-existing liver problems as a specific contraindication for Bentasil use. This is consistent with its classification as a local-acting medicine that has negligible systemic exposure and is generally not expected to interfere significantly with major liver functions.

Q: Do Bentasil side effects usually go away after a few weeks?

A: The local effects sometimes experienced, such as a stinging sensation or minor irritation, are noted in regulatory documents as generally mild. The documents indicate these effects may lessen over time, although a specific timeline like 'a few weeks' is not formally stated in the labeling.

Q: Does Bentasil require any special monitoring or regular blood tests?

A: Consistent with its status as an over-the-counter, local agent, official product information does not list any requirements for special medical monitoring, regular blood tests, or other clinical surveillance during its use.

Q: Can Bentasil cause changes in mood or anxiety?

A: Official regulatory documents primarily classify the documented side effects under local effects and severe allergic reactions. Changes in mood or anxiety are not documented among the officially reported adverse reactions associated with use at the labeled dose.

Q: Does Bentasil interact with herbal remedies like St. John's Wort?

A: Regulatory labeling documents no specific systemic drug-drug interactions, including those with common herbal remedies like St. John's Wort. The active components are not expected to interfere with the metabolism of other substances due to their negligible systemic exposure.

Q: Can Bentasil be crushed or split if a person has trouble swallowing?

A: For the lozenge form, the official method of administration is dissolving the unit slowly in the mouth to achieve the intended localized effect. The administration instructions do not include alternative methods like chewing, breaking, or crushing the product.

Q: Can Bentasil change how alcohol affects the body?

A: Official regulatory documents do not list any specific interaction or timing constraints regarding the co-administration of Bentasil with alcohol. This lack of restriction is in line with the drug's intended use as a local agent with negligible systemic exposure.

Q: Are there any specific dietary restrictions while taking Bentasil?

A: Regulatory labeling does not list any mandatory food or dietary restrictions to follow while using Bentasil. The medicine's local action is generally not dependent on specific meal timing or the avoidance of certain foods.

Q: What is the difference between the immediate-release and extended-release versions of Bentasil?

A: Regulatory documents describe the purpose of Bentasil's local forms, like the lozenge, as providing temporary relief as it slowly dissolves. The medicine is not officially categorized into distinct immediate-release or extended-release systemic versions typically associated with drugs that rely on absorption into the bloodstream.

Q: Does taking Bentasil affect driving or operating machinery?

A: Official safety documentation for the active components in Bentasil states that there are no known effects on the user's ability to drive or operate machinery.

Q: Is it true that Bentasil might interact with grapefruit?

A: Official regulatory labeling does not document any specific food or beverage interactions, including those with grapefruit. This is consistent with its negligible systemic exposure, meaning it is not expected to interfere with the metabolic pathways that grapefruit affects.

Q: Can Bentasil cause stomach upset?

A: Gastrointestinal symptoms are not included among the commonly reported side effects of Bentasil in its official safety profile. However, regulatory review of the component Eucalyptol has indicated that it was occasionally associated with mild-to-moderate gastrointestinal symptoms in certain studies.

Q: What types of food interactions are mentioned for Bentasil?

A: Official regulatory documents on Bentasil do not mention any specific food interactions. The labeling is primarily concerned with systemic drug-drug interactions, of which none are listed due to the product’s local action.

Q: What should a patient do if they accidentally take too much Bentasil?

A: Official warnings and guidance specify that in cases of suspected overdose, contacting a Poison Control Center or seeking medical help immediately is recommended, even if no symptoms are present.

Q: Can I stop taking Bentasil once my symptoms improve?

A: The official definition of Bentasil as an intermittent, symptom-driven intervention means administration is based on the presence of temporary symptoms. Use is generally intended for when temporary relief is needed.

How should Bentasil be stored and disposed of?

How to Store and Dispose of Bentasil

Official regulatory guidelines define specific conditions for storing and disposing of Bentasil, which is an oil-based preparation containing volatile components.

Storage Category Official Requirements
Temperature Store at room temperature, typically between 15 C and 30 C.
Protection The container must be kept tightly closed to prevent the evaporation of volatile oils and be protected from excessive heat, freezing, and direct light.
Child Safety Keep the product out of the sight and reach of children (mandatory).
Disposal Do not dispose of unused or expired product into household waste or down the drain. Disposal must follow local laws and regulations using an authorized special waste or drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bentasil found in:

A-Z Index: